Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Net Margin (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Net Margin for 5 consecutive years, with 82.97% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 2052.0% to 82.97% in Q4 2025 year-over-year; TTM through Dec 2025 was 104.98%, a 9628.0% increase, with the full-year FY2025 number at 106.41%, up 9691.0% from a year prior.
  • Net Margin was 82.97% for Q4 2025 at Rhythm Pharmaceuticals, up from 103.13% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 527.99% in Q4 2022 to a low of 160714.29% in Q1 2021.
  • A 5-year average of 9406.44% and a median of 219.79% in 2023 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: skyrocketed 15720754bps in 2022, then plummeted -69979bps in 2023.
  • Rhythm Pharmaceuticals' Net Margin stood at 2798.84% in 2021, then skyrocketed by 119bps to 527.99% in 2022, then plummeted by -133bps to 171.8% in 2023, then surged by 40bps to 103.5% in 2024, then grew by 20bps to 82.97% in 2025.
  • Per Business Quant, the three most recent readings for RYTM's Net Margin are 82.97% (Q4 2025), 103.13% (Q3 2025), and 98.93% (Q2 2025).